TY  - JOUR 
AU  - López-Iglesias, Ana-Alicia
AU  - Herrero, Ana B
AU  - San Segundo, Laura
AU  - González-Méndez, Lorena
AU  - Hernández-García, Susana
AU  - Misiewicz-Krzeminska, Irena
AU  - Quwaider, Dalia
AU  - Martín-Sánchez, Montserrat
AU  - Primo, Daniel
AU  - Paíno Gómez, María Teresa
AU  - Bergsagel, Leif
AU  - Mehrling, Thomas
AU  - González Díaz, Marcos
AU  - San Miguel Izquierdo, Jesús Fernando
AU  - Mateos Manteca, María Victoria
AU  - Gutiérrez Gutiérrez, Norma Carmen
AU  - Garayoa Berrueta, Mercedes
AU  - Ocio San Miguel, Enrique M.
PY  - 2017
SN  - 1756-8722
UR  - http://hdl.handle.net/10366/135839
AB  - Abstract
Background

Despite recent advances in the treatment of multiple myeloma (MM), the prognosis of most patients remains poor, and resistance to traditional and new drugs frequently occurs. EDO-S101 is a novel therapeutic agent conceived as...
LA  - eng
PB  - BioMed Central
KW  - MEDICINE
KW  - multiple myeloma
KW  - Oncology
KW  - EDO-S101
KW  - Hematology
KW  - DNA damage
KW  - homologous recombination
KW  - Bendamustine
TI  - Preclinical anti-myeloma activity of EDOS101, a new bendamustine-derived molecule with added HDACi activity,through potent DNA damage induction and impairment of DNA repair
T2  - EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
DO  - 10.1186/s13045-017-0495-y
ER  -